Clinical Trials Logo

Lymphoma, Diffuse clinical trials

View clinical trials related to Lymphoma, Diffuse.

Filter by:
  • None
  • Page 1

NCT ID: NCT00596804 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

Start date: March 2004
Phase: Phase 1/Phase 2
Study type: Interventional

This study is being done to assess the safety and tolerance of different doses of humanized hA20 in patients with NHL.

NCT ID: NCT00455897 Terminated - Clinical trials for Lymphoma, Non-Hodgkin

CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma

Start date: December 2006
Phase: Phase 2
Study type: Interventional

The primary goal of this study is to determine the effects (good and bad) of Granulocyte-macrophage colony stimulating factor (GM-CSF) in combination with Cytoxan, Adriamycin, Vincristine, Prednisone, Rituximab (CHOP-R) on diffuse Large B cell Non-Hodgkin's lymphoma (DLBCL). The standard of care for DLBCL is the combination of drugs known as CHOP-Rituximab (CHOP-R). The drugs that make up CHOP-R are the chemotherapy drugs cyclophosphamide, doxorubicin and vincristine, prednisone and rituximab. GM-CSF is a drug that stimulates the immune system by increasing the numbers of white blood cells. Previous research has shown that GM-CSF might help rituximab to be more effective in treating lymphoma.